SELLAS Life Sciences Group Inc. Stock News

Galena Biopharma (SLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

- Announced Independent Data Monitoring Committee's (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: IDMC to Reconvene in

- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential –

– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Patients Treatment and Follow-Up Without Any Modific

SELLAS Life Sciences Group, Inc. is a late-stage biotech company with a leading drug candidate, Galinpepimut-S, or GPS, that has a 44% probability of success and a potential 9x return. GPS is an immun

NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) --  SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the develop

- Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April -

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the developme

-  Update on the Phase 3 REGAL Clinical Trial of GPS in Acute Myeloid Leukemia (AML) - -  Update on the Phase 2a Clinical Trial of SLS009 in relapsed/refractory AML, including topline data - NEW YOR

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the developme

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the developme

- All key study objectives regarding pharmacokinetic, pharmacodynamic, safety, and clinical activity were met - - Complete remission (CR) achieved after three months of treatment with duration of eigh

NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the developme

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the developmen

NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the developme